# OnVagus

Source: https://onco.cc/companies/onvagus/  
OnCo record `onvagus` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

OnVagus is developing a non-invasive device that stimulates the vagus nerve to prevent or reverse cancer cachexia, the weight and muscle loss that many people with cancer experience.

## Summary

OnVagus, Inc., founded in 2022 according to the company, develops a non-invasive device acting on the gut-brain axis to prevent and reverse cancer-associated cachexia, without drugs, needles or surgery; the company states the device reverses weight loss, muscle atrophy, anorexia and inflammation, and these claims are the company's own. In fiscal year 2026 NCI awarded it USD 398,525 under SBIR award 1R44CA298354-01A1 for neuromodulation of the gut-brain axis in cancer cachexia.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: OnVagus, Inc.; ONVAGUS, INC.
- HQ: Woodland Hills, CA
- Type: devices
- Website: https://www.onvagus.com/

## Notes

- No named product on the company website. Read on onvagus.com and NIH RePORTER on 4 November 2026.

## Sources

- Official website: https://www.onvagus.com/
- NIH RePORTER: SBIR award 1R44CA298354-01A1: https://reporter.nih.gov/project-details/11313729

## Connected records

- fronts: [Devices & Physical Therapies](https://onco.cc/fronts/devices/), [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)
- technologies: [Cachexia-directed therapy (GDF-15 blockade)](https://onco.cc/technologies/cachexia-therapy/)

---
JSON: https://onco.cc/api/v1/entities/onvagus.json